2Coleman R E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies[J]. Cancer Treat Rev, 2001,27:165- 176.
3Wilson M A,Calhoun F W. The distribution of skeletal metastases in breast and pulmonary cancer: concise communication [J].J Nucl Med,1981,22:594-597.
4Coleman R E. Skeletal complications of malignancy[J].Cancer, 1997,80(8 Suppl) : 1588-1594.
5Ohashi R, Takahashi K, Miura K, Ishiwata T, Sakuraba S, Fukuchi Y. Prognostic factors in patients with inoperable non- small cell lung cancer-an analysis of long-term survival patients [J]. Gan To Kagaku Ryoho, 2006,33 : 1595-1602.
6Albain K S, Crowley J J, LeBlane M, Livingston R B. Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience[J]. J Clin Oncol, 1991, 9:1618 -1626.
7Vinolas N,Molina R,Galan M C,Casas F,Callejas M A,Filella X,et al. Tumor markers in response monitoring and prognosis of non small cell lung cancer:preliminary report[J]. Anticancer Res,1998,18(1B) :631- 634.
8Merrick M V,Merrick J M. Bone scintigraphy in lung cancer:a reappraisal[J]. Br J Radiol, 1986,59: 1185 1194.
9Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer:a retrospective study[J]. Lung Cancer, 2007,57:229-232.
10Lipton A,Cook R,Saad F,Major P,Garnero P,Terpos E,et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and el crated bone resorption receiving zoledronic acid[J]. Cancer, 2008,113 : 193-201.
